KEY FEATURES
| Full Name | Interferon Alpha 2 |
|---|---|
| Synonym | IFNA2A; IFNA2B; IFNA2C; LeIF A; Alpha-2a Interferon; Interferon Alpha 2b; Interferon Alpha A |
| Assay Type | Sandwich |
| Reactivity | Human |
| Range | 15.6-1000pg/mL |
| Sensitivity | 6.2pg/mL |
| Sample Type | Serum,plasma and other biological fluids |
| Sample Volume | 100μL |
| Detection Wavelength | OD450 |
| Transportation Temperature | 2-8°C |
| Specificity | The kit detected Human IFNa2 in the samples and no significant cross-species reactions were found |
| Microplate | 96-wells plate breakable into 12 x 8 wells strip |
TEST PRINCIPLE
| This ELISA kit uses the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Human IFNa2. Standards or samples are added to the micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human IFNa2 and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human IFNa2, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The OD value is proportional to the concentration of Human IFNa2. You can calculate the concentration of Human IFNa2 in the samples by comparing the OD of the samples to the standard curve. |
ELISA KIT COMPONENTS
Upon receipt, unpack promptly and store as recommended in the instructions.
| Components | Specifications | Storage and Notes |
|---|---|---|
| Micro Plate | 96T: 8 wells×12 strips 48T: 8 wells×6 strips | Unopened: -20°C, 12 months Unused: Put it back in the aluminum foil bag and seal it, store it at -20°C. |
| Reference Standard | 96T: 2 vials 48T: 1 vial | Unopened: -20°C, 12 months Please use freshly dissolved standards for each experiment. Discard any unused standards after dissolution. |
| Biotinylated Detection Ab Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C, 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
| HRP Conjugate Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C(Protect from light), 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
| Biotinylated Detection Ab Diluent | 14mL×1 | 2-8℃, 12 months |
| HRP Conjugate Diluent | 14mL×1 | 2-8℃, 12 months |
| Reference Standard & Sample Diluent | 20mL×1 | 2-8℃, 12 months |
| Washing Buffer Concentrate (25×) | 30mL×1 | 2-8℃, 12 months |
| Substrate Reagent(TMB) | 10mL×1 | 2-8°C(Protect from light),12 months |
| Stop Solution | 7mL×1 | 2-8°C/Room temperature |
ASSAY PROCEDURES
TYPICAL DATA
Human IFNa2 ELISA Standard Curve
Typical data are for reference only and curves should be replotted for each experiment. The Logistics function is recommended for fitting.
PRECISION
Intra-Assay Precision (Precision within an assay): Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): Three samples of known concentration were tested in twenty separate assays to assess inter-assay precision. Assays were performed by at least three technicians using two lots of components.
| Intra-assay Precision | Inter-assay Precision | |||||
|---|---|---|---|---|---|---|
| Sample | 1 | 2 | 3 | 1 | 2 | 3 |
| n | 20 | 20 | 20 | 20 | 20 | 20 |
| Mean (pg/mL) | 54.4 | 128.89 | 366.61 | 57.48 | 122.38 | 347.72 |
| Standard deviation | 3 | 6.91 | 15.21 | 3.32 | 5.16 | 15.44 |
| CV(%) | 5.51 | 5.36 | 4.15 | 5.77 | 4.22 | 4.44 |
RECOVERY
The recovery of Human IFNa2 spiked to three different levels in samples throughout the range of the assay in various matrices was evaluated.
| Sample Type | Range (%) | Average Recovery (%) |
|---|---|---|
| Serum(n=8) | 84-98 | 90 |
| EDTA plasma (n=8) | 91-108 | 98 |
| Cell culture media (n=8) | 93-110 | 100 |
LINEARITY
To assess the linearity of the assay, samples containing and/or spiked with high concentrations of Human IFNa2 in various matrices were diluted with the Reference Standard & Sample Diluent to produce samples with values within the dynamic range of the assay.
Products associated with IFNA2 ELISA Kits
| IFNAR1 ELISA Kit | publications with IFNA2 and IFNAR1 |
| STAT2 ELISA Kit | publications with IFNA2 and STAT2 |
| IFNAR2 ELISA Kit | publications with IFNA2 and IFNAR2 |
| TYK2 ELISA Kit | publications with IFNA2 and TYK2 |
| IRF9 ELISA Kit | publications with IFNA2 and IRF9 |
| IRF1 ELISA Kit | publications with IFNA2 and IRF1 |
| IL2 ELISA Kit | publications with IFNA2 and IL2 |
| IRF2 ELISA Kit | publications with IFNA2 and IRF2 |
| IFNG ELISA Kit | publications with IFNA2 and IFNG |
| IFNA5 ELISA Kit | publications with IFNA2 and IFNA5 |
Pathways associated with IFNA2 ELISA Kit
| Autoimmune Thyroid Disease Pathway | Autoimmune Thyroid Disease Pathway |
| Cytokine Signaling In Immune System Pathway | Cytokine Signaling In Immune System Pathway |
| Cytokine-cytokine Receptor Interaction Pathway | Cytokine-cytokine Receptor Interaction Pathway |
| Cytosolic DNA-sensing Pathway | Cytosolic DNA-sensing Pathway |
| Factors Involved In Megakaryocyte Development And Platelet Production Pathway | Factors Involved In Megakaryocyte Development And Platelet Production Pathway |
| Hemostasis Pathway | Hemostasis Pathway |
| Hepatitis B Pathway | Hepatitis B Pathway |
Diseases associated with IFNA2 ELISA Kit
| Skin Diseases | publications with IFNA2 and Skin Diseases |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | publications with IFNA2 and Leukemia, Myelogenous, Chronic, BCR-ABL Positive |
| Carcinoma, Renal Cell | publications with IFNA2 and Carcinoma, Renal Cell |
| Anemia | publications with IFNA2 and Anemia |
| Fever | publications with IFNA2 and Fever |
| Lymphoma, Non-Hodgkin | publications with IFNA2 and Lymphoma, Non-Hodgkin |
| Neutropenia | publications with IFNA2 and Neutropenia |
| Fatigue | publications with IFNA2 and Fatigue |
| Mental Disorders | publications with IFNA2 and Mental Disorders |
| Thrombocytopenia | publications with IFNA2 and Thrombocytopenia |
